Showing results (231-240 of 288) with videos related to
Sort By:
Pageof 29
Blood|January 13, 2016
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.Blood|December 1, 2007
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Anthony H Goldstone, Susan M Richards, Hillard M Lazarus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.Blood|October 16, 2009
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)David I Marks, Elisabeth M Paietta, Anthony V Moorman, et al.Blood|February 27, 2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Adele K Fielding, Jacob M Rowe, Susan M Richards, et al.British Journal of Haematology|March 29, 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trialChezi Ganzel, Xin V Wang, Jacob M Rowe, et al.American Journal of Hematology|October 30, 2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult diseaseMark R Litzow, Xin V Wang, Martin P Carroll, et al.Blood|June 12, 2010
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosisVikas Gupta, Martin S Tallman, Wensheng He, et al.Acta Haematologica|September 16, 2016
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic LeukemiaMuhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, et al.Leukemia Research|May 29, 2017
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic TrialsStephen A Strickland, Zhuoxin Sun, Rhett P Ketterling, et al.Pageof 29